Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company developing the oral CETP inhibitor obicetrapib for LDL-C lowering in patients at risk of cardiovascular disease. Through these regulatory documents, investors can review how NewAmsterdam reports its clinical progress, financial position and corporate actions.
Current reports on Form 8-K are used by NewAmsterdam to disclose material events such as quarterly financial results, corporate updates and the publication of investor presentations. For example, the company has filed an 8-K to furnish a press release announcing financial results for a recent quarter and to make an updated corporate investor presentation available as an exhibit. Such filings can give context on research and development spending, cash and marketable securities, and the status of key clinical and regulatory milestones.
NewAmsterdam also uses SEC filings to document equity-related matters, including inducement share option grants made under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). These disclosures outline the size of option grants, vesting schedules and exercise prices for new hires, providing insight into compensation practices and share-based incentives.
On Stock Titan, NewAmsterdam’s SEC filings are updated as they are made available from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections and clarify terminology. Users can quickly locate quarterly and annual reports when filed, review 8-Ks describing clinical and regulatory developments, and examine exhibits such as press releases and corporate presentations. This makes it easier to understand how NewAmsterdam communicates the evolution of its obicetrapib program, its collaboration and licensing arrangements, and other corporate information in its official regulatory record.
NewAmsterdam Pharma (NAMS) filed its Q3 2025 10‑Q, reporting revenue of $348 thousand and a net loss of $72.0 million. Operating expenses totaled $55.5 million, driven by R&D $31.0 million and SG&A $24.5 million. Other items included a $23.8 million loss from warrant fair value changes and $6.7 million of interest income.
Liquidity remains strong with $756.0 million in cash, cash equivalents and marketable securities as of September 30, 2025. During the nine months, the company recognized $16.1 million related to development cost contributions under its Menarini license and recorded initial supply revenue of $348 thousand after signing a Menarini Supply Agreement on August 12, 2025. On August 18, 2025, the EMA validated MAAs for obicetrapib 10 mg monotherapy and the obicetrapib + ezetimibe FDC. The PREVAIL outcomes trial completed enrollment in April 2024 and could conclude as early as the end of 2026 based on minimum follow‑up and event targets.
NewAmsterdam Pharma (NAMS) furnished an update on November 5, 2025, announcing corporate updates and financial results for the quarter ended September 30, 2025. The company also posted an updated corporate investor presentation on its website.
Both the press release and the investor presentation were furnished as Exhibits 99.1 and 99.2, respectively, and are not deemed filed under the Exchange Act or incorporated by reference, except as expressly stated in future filings.
James N. Topper, a director of NewAmsterdam Pharma Co N.V. (ticker: NAMSW), reported a purchase on Form 4. The filing shows a transaction on 09/15/2025 acquiring 660 ordinary shares at a weighted average price of $23.6953. The filing lists two holdings following the reported transaction: 3,028,524 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. Footnotes state the reported price is a weighted average from multiple purchases priced between $23.46 and $23.75. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Topper on 09/17/2025.